Medical Access and Reimbursement in Switzerland

Psilocybin can be used only through FOPH exceptional permission for limited medical use of prohibited narcotics, applied for by the treating physician with patient consent and Swiss residency requirements. The 2025 BAG expert report describes psilocybin permissions as increasing since 2021, but these treatments are not Swissmedic-authorised products and are not routine compulsory-insurance benefits. # #

MDMA can be used only through FOPH exceptional permission for limited medical use or through research approvals, not as a generally authorised Swissmedic medicine. The physician-led exception pathway requires an individual application and does not create routine health-insurance reimbursement. # #

Spravato is Swissmedic-authorised and entered the Specialities List on 1 October 2025 with temporary limitations through 30 September 2028. Reimbursement is restricted by indication, prior insurer approval and administration in listed adult psychiatric centres. # # # #

Ketamine is available as an anaesthetic medicine, but psychiatric use for depression is not the same as Spravato reimbursement. FOPH's 2023 KLV commentary notes that adding ketamine hydrochloride to the tariff for depression and pain was rejected, so reimbursement remains case- and setting-dependent rather than a general depression pathway. #

DMT is controlled in Switzerland. Swissmedic clarified that N,N-DMT is listed as a prohibited controlled substance and that DMT-containing preparations require product-specific assessment; Swiss research has studied DMT, but no routine medical access or reimbursement pathway was verified. # # #

5-MeO-DMT is controlled and no routine medical access or reimbursed treatment pathway was verified. It should be treated separately from FOPH's LSD, psilocybin and MDMA limited-use practice unless a specific exception permit or research approval is documented. # #

No authorised or reimbursed medical pathway for ibogaine was verified in the reviewed Swiss primary sources. Any patient-access claim would need direct evidence of an FOPH exception, Swissmedic authorisation or approved study. #

Ayahuasca is legally sensitive because DMT is controlled while DMT-containing plants are not listed in the same way. Swissmedic's clarification says DMT-containing preparations can still fall under narcotics control depending on product, presentation and context, with cantonal authorities assessing individual cases. No routine medical or reimbursed pathway was verified. #

Mescaline is scheduled in Swiss narcotics lists and no routine medical access or reimbursement pathway was verified. Switzerland's limited-use practice described in official sources centres mainly on LSD, psilocybin and MDMA. # #

2C-B has appeared in Swiss healthy-volunteer research, including a completed comparison study with MDMA and psilocybin, but registry research is not medical access. No authorised or reimbursed 2C-compound pathway was verified. #